文献速递浆细胞疾病白血病

TAZ通过下调MYC在多发性骨髓瘤中发挥抑癌作用

TAZ functions as a tumor suppressor in multiple myeloma by downregulating MYC.
PubMed 文献 · Blood Adv · 2019-01-01

多发性骨髓瘤(MM)常伴MYC扩增和过表达,直接靶向MYC尚不可行。本研究发现,与实体瘤相反,TAZ在血液恶性肿瘤中表达较低,且高表达TAZ与患者预后较好相关。TAZ在MM样本和细胞系中高甲基化,遗传过表达或地西他滨上调TAZ可诱导凋亡,且不依赖经典Hippo成分LATS1或TEAD转录因子。RNA测序显示TAZ过表达抑制MYC转录程序,TAZ表达增加与MYC表达降低相关。

要点

  • TAZ在MM中低表达且高甲基化,高表达与预后较好相关。
  • 过表达或地西他滨上调TAZ诱导MM细胞凋亡,不依赖LATS1/TEAD。
  • TAZ通过抑制MYC转录程序发挥抑癌作用,并与硼替佐米等药物协同。

核心结论

  • TAZ在MM中发挥抑癌作用,其高表达与患者预后较好相关。
  • TAZ通过下调MYC转录程序诱导凋亡,不依赖经典Hippo通路成分LATS1或TEAD。
  • 上调TAZ表达可恢复MM细胞对硼替佐米、曲古抑菌素A和帕比司他等药物的敏感性。

研究设计与样本

  • 研究分析了MM患者样本和一组MM细胞系中TAZ的表达与甲基化状态。
  • 通过遗传过表达TAZ或使用去甲基化剂地西他滨药理学上调TAZ,评估对MM细胞凋亡的影响。
  • 利用RNA测序分析TAZ过表达后的转录程序变化,并在细胞系模型和患者样本中验证TAZ与MYC表达的相关性。

主要发现

  • 与实体瘤不同,TAZ在血液恶性肿瘤中表达较低,高表达TAZ与患者预后较好相关。
  • TAZ在MM患者样本和MM细胞系中呈高甲基化。
  • 遗传过表达TAZ或地西他滨处理上调TAZ可诱导MM细胞凋亡。
  • TAZ诱导的凋亡不依赖LATS1或TEAD转录因子。
  • TAZ过表达抑制MYC转录程序,且TAZ表达增加与MYC表达降低在细胞系模型和患者样本中均相关。

临床怎么用

  • TAZ表达水平或甲基化状态可能作为MM预后评估的潜在标志物。
  • 去甲基化药物(如地西他滨)上调TAZ可能作为抑制MYC活性的替代策略。
  • 上调TAZ表达可能恢复MM对硼替佐米等特定治疗的敏感性,值得进一步探索。

局限性

  • 研究主要基于细胞系模型和患者样本的关联分析,需进一步体内实验验证。
  • TAZ上调诱导凋亡的具体分子机制尚未完全阐明。
  • 临床转化潜力需通过临床试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) is an incurable blood cancer that is often characterized by amplification and overexpression of the MYC oncogene. Despite efforts, direct targeting of MYC is not yet possible; therefore, alternative strategies to inhibit MYC activity are necessary. TAZ is a transcriptional coactivator downstream of the Hippo-signaling pathway that functions as an oncogene in many solid tumors. However, its role in hematological malignancies is largely unexplored. Here, we show that, in contrast to solid tumors, expression of TAZ is lower in hematological malignancies, and that high expression of TAZ correlates with better patient outcomes. We further show that TAZ is hypermethylated in MM patient samples and in a panel of MM cell lines. Genetic overexpression of TAZ or pharmacological upregulation of TAZ by treatment with the demethylating agent decitabine induces apoptosis. Importantly, TAZ-induced apoptosis is independent of canonical Hippo components LATS1 or the TEA-domain family of transcription factors. Instead, RNA-sequencing analysis revealed that overexpression of TAZ represses a MYC transcriptional program and we show that increased TAZ expression correlates with decreased MYC expression in both cell-line models and patient samples. Furthermore, promoter derepression of TAZ expression sensitizes MM cell lines through a reciprocal reduction in MYC expression using additional therapeutics such as bortezomib, trichostatin A, and panobinostat. Our findings uncover an unexpected role for TAZ in MM tumorigenesis and provide a compelling rationale for exploring the therapeutic potential of upregulating TAZ expression to restore sensitivity to specific therapeutics in MM.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Grieve S, Wajnberg G, Lees M, et al. TAZ functions as a tumor suppressor in multiple myeloma by downregulating MYC. Blood Adv. 2019. PMID: 31743393. doi:10.1182/bloodadvances.2019000374

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。